Holen Sie sich die Stockscreener-App
5.155
4.71%
-0.255
Handel nachbörslich:
5.30
0.145
+2.81%
Schlusskurs vom Vortag:
$5.41
Offen:
$5.42
24-Stunden-Volumen:
120.48K
Relative Volume:
0.46
Marktkapitalisierung:
$126.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-20.62
EPS:
-0.25
Netto-Cashflow:
$-47.10M
1W Leistung:
-20.32%
1M Leistung:
-2.92%
6M Leistung:
-33.74%
1J Leistung:
-43.98%
1-Tages-Spanne:
$5.14
$5.45
1-Wochen-Bereich:
$5.14
$6.61
52-Wochen-Spanne:
$4.61
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| OTLK | 5.155 | 126.08M | 0 | -51.50M | -47.10M | -0.25 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com
Learn to Evaluate (OTLK) using the Charts - Stock Traders Daily
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Aterian Investment Partners acquires Outlook Group to support growth - Packaging Gateway
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewswire
Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win | OTLK Stock News - StockTitan
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
(OTLK) Trading Signals - Stock Traders Daily
The United States Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research
Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com
How the (OTLK) price action is used to our Advantage - Stock Traders Daily
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com
ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(OTLK) On The My Stocks Page - Stock Traders Daily
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts - Benzinga
Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India
Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com
Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex
A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics Inc (OTLK) Becoming More Attractive for Investors - Knox Daily
UK Asthma Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
Private equity firms are Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners and were rewarded after market cap rose by US$30m last week - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Outlook Therapeutics Inc [OTLK] Shares Jump Approximately 62.65% Over the Year - Knox Daily
Iovance Therapeutics: Historic Product, Tough Commercial Outlook - Seeking Alpha
Outlook Therapeutics completes NORSE EIGHT enrollment - Investing.com
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics (NASDAQ:OTLK) Price Target Lowered to $33.00 at Ascendiant Capital Markets - Defense World
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):